# Nouscom

**Canonical:** https://apis.io/providers/nouscom/  
**Website:** https://nouscom.com/  
**APIs profiled:** 0

Nouscom AG is a private, clinical-stage immuno-oncology company developing next-generation neoantigen-targeted cancer immunotherapies, founded in 2015 by Riccardo Cortese and Alfredo Nicosia, with headquarters in Basel, Switzerland and research and manufacturing operations in Rome, Italy. Its proprietary viral vector platform — great ape adenovirus and MVA vectors able to encode large neoantigen payloads together with other immunomodulators — is used to build both off-the-shelf and personalized cancer vaccines. The lead program, NOUS-209, targets 209 shared frameshift neoantigens for cancer interception in Lynch Syndrome carriers and for the treatment of dMMR/MSI metastatic colorectal cancer in combination with pembrolizumab; its second clinical program, NOUS-PEV, is a personalized immunotherapy for advanced solid tumors. Nouscom raised an oversubscribed EUR 67.5 million Series C in November 2023, co-led by Andera Partners, Bpifrance (InnoBio 2) and M Ventures. Nouscom is a therapeutics developer, not a software vendor: it publishes no public API, developer portal, SDK or machine-readable API contract, and is profiled here as an identity-only record.

## Kin Score — 4.0 / 100 (minimal)

Scored 2026-09-01 under rubric 0.17.2. Trend: flat (+0.0 from 4.0).

| Facet | Score |
|---|---|
| Discoverability | 53.7 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 2.6 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 2.9 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | yes |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Security (1)

- **Nouscom Domain Security** — TLSv1.3

## Tags

Company, Biotechnology, Immuno-Oncology, Pharmaceuticals, Life Sciences, Clinical Trials, Cancer Immunotherapy, Switzerland, Italy, Private Company

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/nouscom/). Scores are computed from the provider's own public artifacts under a published rubric.